Status:
COMPLETED
Non-Comparative Study To Evaluate Changes In FMD After Quinapril Therapy In Hypertensive Women
Lead Sponsor:
Pfizer
Conditions:
Menopause
Hypertension
Eligibility:
FEMALE
18-75 years
Phase:
PHASE4
Brief Summary
ACE inhibitors are thought to modify the endothelium in a number of ways. Quinapril is an effective and well-tolerated ACE-I for the treatment of patients with hypertension and congestive heart failur...
Eligibility Criteria
Inclusion
- pathological baseline FMD (\< 5%) at screening
- women in post-menopause at least for 2 years (post-menopausal defined as having amenorrhea for Å' 2 years)
- mild or moderate hypertension (BP \> 140/90 mmHg)
Exclusion
- uncontrolled severe hypertension (BP \> 180/110 mmHg)
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
End Date :
May 1 2005
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00147524
Start Date
October 1 2003
End Date
May 1 2005
Last Update
April 30 2007
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Hódmezővásárhely, Csongrád megye, Hungary
2
Pfizer Investigational Site
Budapest, Hungary
3
Pfizer Investigational Site
Mátészalka, Hungary
4
Pfizer Investigational Site
Szeged, Hungary